COMMUNIQUÉS West-GlobeNewswire

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
12/08/2026
ISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab- [...]
Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones
12/08/2026
PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed sales subject to [...]
Hyperion DeFi Reports 2Q 2026 Financial Results with Another Record Quarterly Net Income and Strong Operating Momentum
12/08/2026
Company Reports Record $31.0M Net Income and $53.7M Adjusted EBITDA ( 8 ) Announcing New HAUS Agreement with Entropy, an Upcoming HIP-3 Deployer 1 Million HYPE Tokens Redeployed to Support HIP-3 & HIP-4 Markets [...]
Earth Science Tech, Inc. (ETST) Expands National Footprint with Strategic Acquisition of California Compounding Pharmacy, Meduvo LLC
12/08/2026
MIAMI, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on a diversified portfolio, today announced the acquisition of Meduvo LLC, a [...]
Rampart retire son recours contre la décision d’invalidation de l’USPTO
12/08/2026
ST. PAUL, Minnesota, 12 août 2026 (GLOBE NEWSWIRE) -- Egg Medical a annoncé que Rampart IC, LLC (« Rampart ») avait retiré son recours contre la décision de réexamen de l’USPTO, selon laquelle les revendications du [...]
NOTICE TO DISREGARD -- Leading Edge Health Inc
13/08/2026
LAS VEGAS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- We are advised by VITALIBOOST LLC that journalists and other readers should disregard the news release, “Load Boost: Semenax, Volume Pills or SemEnhance - Which is Best Load [...]
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
12/08/2026
The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to Support NurExone’s Clinical Pipeline and Planned Commercial Production TORONTO and HAIFA, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc [...]
Park Dental Partners Announces Second Quarter 2026 Results
12/08/2026
MINNEAPOLIS, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK) and affiliated dental practices (“Park Dental Partners,” “we,” “our,” “us,” or the “Company”) today reported its second quarter [...]
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
12/08/2026
- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new [...]
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
12/08/2026
- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program - Upfront proceeds [...]
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
12/08/2026
Completed enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease (CeD); top-line Cohort 1 data reaffirmed for Q4 2026 Cohort 2 (mucosal healing) enhanced to enroll up to 40 patients [...]
BIO GREEN MED SOLUTION REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
12/08/2026
KUALA LUMPUR, MALAYSIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; "BGMS" or the "Company"), a diversified company engaged primarily in the provision of fire safety protection and [...]
Range Impact Reports 2Q 2026 Financial Results
12/08/2026
CLEVELAND, OHIO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming, and redeveloping legacy coal mines throughout [...]
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
12/08/2026
Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 [...]
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
12/08/2026
Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L Consolidation Therapy [...]
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
12/08/2026
On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and [...]
SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
12/08/2026
Added 3 top-rated children’s hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enrollment in the NEUTRALIZE-AKI pivotal clinical [...]
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
12/08/2026
– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway [...]
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
12/08/2026
Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV C-FORWARD Phase 3 [...]

Pages